The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction
Abstract
BACKGROUND: Although aspirin has been shown to protect patients from acute myocardial infarction (AMI), the effect of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) is not clear. OBJECTIVE: To determine whether NSAIDs have a similar effect or whether they differ in their effect on the risk of AMI. METHODS: We performed a case-control study of AMI in a large health care database containing information on all filled prescriptions, hospitalizations, diagnoses, and procedures for all patients covered by the New Jersey Medicaid or Medicare and Pharmaceutical Assistance for the Aged and Disabled programs. We identified 4425 patients hospitalized for AMI between January 1, 1991, and December 31, 1995, and 17 700 control subjects. Multivariate models were constructed to control for potential confounders. RESULTS: A quarter of the cases and controls had filled a prescription for an NSAID in the 6 months before theirAMI (cases) or a randomly assigned index date (controls); 9% had filled a prescription for an NSAID that overlapped with their date of AMI or index date. Overall, NSAID users had the same risk of AMI as nonusers, whether such use was measured on the index date (adjusted odds ratio, 1.04; 95% confidence interval, 0.92-1.18; P =.55) or at any time in the prior 6 months (adjusted odds ratio, 1.00; 95% confidence interval, 0.92-1.08; P =.92). However, use of naproxen was associated with a significant reduction in the risk of AMI (adjusted odds ratio, 0.84; 95% confidence interval, 0.72-0.98; P =.03). CONCLUSIONS: Although NSAIDs have anti-inflammatory and antiplatelet effects similar to those of aspirin, we did not find that these drugs confer a protective effect against AMI. However, use of one specific NSAID, naproxen, appeared to be associated with a reduced rate of AMI, an effect recently suggested by a large randomized controlled trial as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 2×
“In addition, a comorbidity index was calculated using inpatient and outpatient diagnoses, according to the method of Deyo et al.(17) Health care resource use was determined for the 180 days before the index date, including the number of hospitalizations, number of different drug prescriptions, and nursing home use.”
MethodInhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Cited by
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., & Roth, G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.234s · Cited by 671
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 614
Hippisley-Cox, J., & Coupland, C. (2005) · BMJ · doi:10.1136/bmj.330.7504.1366 · Cited by 561
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Solomon, D. H., Schneeweiss, S., Glynn, R. J., Kiyota, Y., Levin, R., Mogun, H., & Avorn, J. (2004) · Circulation · doi:10.1161/01.cir.0000127578.21885.3e · Cited by 509
Self-citationCOX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Farkouh, M. E., Kirshner, H., Harrington, R. A., Ruland, S., Verheugt, F. W., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16894-3 · Cited by 490
Gislason, G. H., Jacobsen, S., Rasmussen, J. N., Rasmussen, S., Buch, P., Friberg, J., Schramm, T. K., Abildstrom, S. Z., Køber, L., Madsen, M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.616219 · Cited by 447
An Overview of Clinical Pharmacology of Ibuprofen
Bushra, R., & Aslam, N. (2010) · Oman Medical Journal · doi:10.5001/omj.2010.49 · Cited by 416
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., & Fuchs, C. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595793 · Cited by 319
Gislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Schramm, T. K., Hansen, M. L., Fosbøl, E. L., Sørensen, R., Folke, F., Buch, P., Gadsbøll, N., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.525 · Cited by 295
Johnsen, S. P. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.9.978 · Cited by 288
Mamdani, M., Rochon, P., Juurlink, D. N., Anderson, G. M., Kopp, A., Naglie, G., Austin, P. C., & Laupacis, A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.481 · Cited by 281
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
Capone, M. L., Sciulli, M. G., Tacconelli, S., Grana, M., Ricciotti, E., Renda, G., Di Gregorio, P., Merciaro, G., & Patrignani, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.045 · Cited by 279
Kurth, T., Glynn, R. J., Walker, A. M., Chan, K. A., Buring, J. E., Hennekens, C. H., & Gaziano, J. M. (2003) · Circulation · doi:10.1161/01.cir.0000087593.07533.9b · Cited by 254
Self-citationGaziano, J. M., & Gibson, C. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.02.020 · Cited by 30
Metadata
- Authors
- Solomon, D. H., Glynn, R. J., Levin, R., & Avorn, J.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2002-05-27
- Volume
- 162
- Issue
- 10
- Pages
- 1099
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2143995569
- Cited by
- 234
- References
- 3
- FWCI
- 22.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.